Adverse Events and Androgen Receptor Signaling Inhibitors in the Treatment of Prostate Cancer: A Systematic Review and Multivariate Network Meta-analysis-Reference-Cited by-同舟云学术

Adverse Events and Androgen Receptor Signaling Inhibitors in the Treatment of Prostate Cancer: A Systematic Review and Multivariate Network Meta-analysis

Published:2023-06 Issue:3 Volume:6 Page:237-250
ISSN:2588-9311
Container-title:European Urology Oncology
language:en
Short-container-title:European Urology Oncology

Author:

Cao Brent,Kim Melissa,Reizine Natalie M.,Moreira Daniel M.

Publisher

Elsevier BV

Subject

Urology,Radiology, Nuclear Medicine and imaging,Oncology,Surgery

Reference71 articles.

1. Cancer statistics, 2022;Siegel;CA Cancer J Clin,2022

2. Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches;Karantanos;Oncogene,2013

3. Profiling prostate cancer therapeutic resistance;Wade;Int J Mol Sci,2018

4. Metastatic castration-resistant prostate cancer previously treated with docetaxel-based chemotherapy: treatment patterns from the PROXIMA prospective registry;Akaza;J Glob Oncol,2018

5. Recent trends in the management of advanced prostate cancer;Ritch;F1000Res,2018

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical Outcomes and Prognostic Factors in Nonmetastatic Castration-Resistant Prostate Cancer Treated with Androgen Receptor Signaling Inhibitors Therapy;Cancers;2024-07-26

2. Adverse events in men with advanced prostate cancer treated with androgen biosynthesis inhibitors and androgen receptor inhibitors;JNCI: Journal of the National Cancer Institute;2024-07-25

3. Cardiovascular Events and Androgen Receptor Signaling Inhibitors in Advanced Prostate Cancer;JAMA Oncology;2024-07-01

4. Role of Lutetium Radioligand Therapy in Prostate Cancer;Cancers;2024-07-01

5. Comparative effectiveness of multiple androgen receptor signaling inhibitor medicines with androgen deprivation therapy for metastatic hormone-sensitive prostate cancer: a study in the real world;Frontiers in Oncology;2024-04-18